Perrigo OTC Pharmaceutical Sales Up More Than 20% In Third Quarter
This article was originally published in The Tan Sheet
Executive Summary
Perrigo OTC pharmaceutical sales jumped more than 20% in the fiscal third quarter ended April 3, the company reported May 11. However, on a year-to-date basis, the private labeler experienced only a modest increase in OTC sales, the company says in its 10-Q filing with the Securities & Exchange Commission.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning